Denedra Threatt

Denedra Threatt supports the Centers for Disease Control and Prevention’s Office of Acquisition Services in executing mission-critical procurement activities that enable public health preparedness and scientific response. She manages a diverse portfolio of contracts focused on laboratory diagnostics, biomedical research tools, and data infrastructure essential for disease surveillance and outbreak response. Her work ensures the timely acquisition of specialized equipment, analytical services, and technical solutions that underpin CDC’s ability to detect, analyze, and mitigate emerging health threats across the nation. Threatt maintains strategic relationships with key contractors including General Dynamics Information Technology, GlaxoSmithKline, MRIGLOBAL, and Cepheid, reflecting a reliance on industry leaders in diagnostic instrumentation, clinical testing, and advanced laboratory systems. Her contracting patterns emphasize long-term partnerships with vendors capable of delivering high-complexity, regulated products and services that meet stringent federal standards for accuracy, reliability, and biosecurity. These collaborations are often structured through performance-based, indefinite-delivery/indefinite-quantity (IDIQ) mechanisms to ensure agility in responding to dynamic public health needs. Her procurement approach prioritizes open competition, with nearly 80% of awards issued without set-aside restrictions, indicating a focus on technical capability over socioeconomic categorization. Nevertheless, she consistently facilitates opportunities for small businesses, with approximately 18% of awards designated as total small business set-asides under FAR 19.5, and a smaller but meaningful portion allocated through 8(a) competed programs, demonstrating balanced support for innovation and socioeconomic equity. Threatt’s primary procurement focus lies in NAICS 334516 (analytical laboratory instrument manufacturing) and 621511 (medical laboratories), reflecting deep expertise in acquiring next-generation sequencing platforms, real-time PCR systems, and clinical diagnostic kits. She also supports custom software development and professional scientific services under NAICS 541511 and 541990, ensuring CDC’s data analytics and epidemiological modeling capabilities remain at the forefront of public health science.